Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Belgian Group of Digestive Oncology
- Target Recruit Count
- 134
- Registration Number
- NCT05472259
- Locations
- 🇧🇪
AZ Imelda, Bonheiden, Belgium
🇧🇪CHU Ambroise Paré, Mons, Belgium
🇧🇪Grand Hopital de Charleroi, Charleroi, Belgium
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 200
- Registration Number
- NCT05464030
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., Fresno, California, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05445440
- Locations
- 🇺🇸
Quotient Sciences Miami, Miami, Florida, United States
FOLFIRINOX + NIS793 in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Colin D. Weekes, M.D., PhD
- Target Recruit Count
- 4
- Registration Number
- NCT05417386
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT05412082
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 177
- Registration Number
- NCT05383352
- Locations
- 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺Flinders Medical Centre, Bedford Park, Australia
🇦🇺Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 104
- Registration Number
- NCT05382442
- Locations
- 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
A Study of ASP3082 in Adults With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 541
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
Florida Cancer Specialist, Lake Mary, Florida, United States
🇺🇸Case Western, Cleveland, Ohio, United States
🇺🇸University of Wisconsin Hospital, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.